Bioequivalence and Bioavailability Forum

Study Design- Two treatment or Four treatment NK 2023-01-23 09:38
- Study Design- Two treatment or Four treatment dshah 2023-01-23 10:43
  - Study Design- Two treatment or Four treatment NK 2023-01-24 03:37
- Study Design- Two treatment or Four treatment ElMaestro 2023-01-23 15:05
  - Study Design- Two treatment or Four treatment Relaxation 2023-01-23 16:10

Washout based on mean ± SD of t½ Imph 2022-09-25 13:52
- Washout based on mean ± SD of t½ Helmut 2022-09-25 16:08
  - Washout based on mean ± SD of t½ Imph 2022-09-26 15:24
    - Washout based on mean ± SD of t½ Shuanghe 2022-09-26 17:34
    - Washout based on mean ± SD of t½ Helmut 2022-09-26 17:35
    - If you have data… Helmut 2022-09-27 11:52
      - If you have data… Imph 2022-10-25 09:21

Initial dose and design issues abridged submission daily ER vs BID IR alejandro_jo1990 2022-09-15 15:35

Bioequivalence of mirabegron 50 mg extended release Tablet Ibrahim Komeil 2021-02-20 11:36
- Replicate designs based on information of 2×2×2 design Helmut 2021-02-20 14:50
  - Replicate designs based on information of 2×2×2 design Ibrahim Komeil 2021-02-20 18:34
    - Assumption of authority? Helmut 2021-02-20 20:50
- Bioequivalence of mirabegron 50 mg extended release Tablet jishnu 2022-08-04 09:09
- Bioequivalence of mirabegron 50 mg extended release Tablet qualityassurance 2022-08-04 15:47

Could we design the RCT as a non-inferiority trial at this situation? dennis001 2022-07-24 17:39
- Non-Superiority Helmut 2022-07-25 16:37
  - Non-Superiority dennis001 2022-07-26 02:32
    - Non-Superiority Helmut 2022-07-26 15:04
      - Non-Superiority dennis001 2022-07-27 05:18
        
        Placebo effect Helmut 2022-07-27 12:17
- Could we design the RCT as a non-inferiority trial at this situation? ElMaestro 2022-07-26 12:44
  - Could we design the RCT as a non-inferiority trial at this situation? dennis001 2022-07-27 05:21

Drug-drug interaction with two different route of administration Mr.Rao 2022-07-13 13:51
- Drug-drug interaction with two different route of administration Mr.Rao 2022-07-14 09:05
  - Drug-drug interaction with two different route of administration dshah 2022-07-20 10:27
    - Drug-drug interaction with two different route of administration Mr.Rao 2022-07-21 11:24
      - Drug-drug interaction with two different route of administration dshah 2022-07-21 18:51
        
        Drug-drug interaction with two different route of administration Mr.Rao 2022-07-22 07:23
        
        Drug-drug interaction with two different route of administration Mr.Rao 2022-07-27 08:31
        
        Interpreting results of a DDI study Helmut 2022-07-27 09:52

‘Two-at-a-Time’ approach with >3 treatments Helmut 2022-06-12 11:37
- ‘Two-at-a-Time’ approach with >3 treatments Shuanghe 2022-06-12 19:02
  - ‘Two-at-a-Time’ approach with >3 treatments Helmut 2022-06-12 20:10
    - ‘Two-at-a-Time’ approach with >3 treatments Shuanghe 2022-07-10 00:05
      - ‘Two-at-a-Time’ approach; ≥3 treatments: new 🇷 script Helmut 2022-07-10 16:02
        
        ‘Two-at-a-Time’ approach; ≥3 treatments: new 🇷 script Shuanghe 2022-07-13 15:35
        
        You’re a NE🇷D! Helmut 2022-07-13 16:46

BE study Design for Rivaroxaban 20 mg Tricky TAB 2022-07-04 11:33
- Rivaroxaban: FDA and others Helmut 2022-07-04 13:19
  - Rivaroxaban: FDA and others Tricky TAB 2022-07-05 06:42
    - Rivaroxaban: FDA and others Helmut 2022-07-05 09:49
      - Rivaroxaban: FDA and others Tricky TAB 2022-07-06 06:52

PK time points Vaibhav 2022-06-23 21:31
- PK time points dshah 2022-06-24 11:29

Switchability with replicate design studies Achievwin 2022-05-20 04:44
- Switchability = IBE Helmut 2022-05-20 09:17
  - Switchability = IBE Achievwin 2022-05-20 14:19
    - S × F interaction Helmut 2022-05-20 15:33
      - S × F interaction Achievwin 2022-05-20 23:32

Hydrocortisone BE studies for UK HallaGulla 2022-05-16 17:37

Coefficient variation intra subject variability of librax Bebac user 2022-02-17 19:31
- Coefficient variation intra subject variability of librax khageswara Rao 2022-02-28 07:54
  - Coefficient variation intra subject variability of librax Bebac user 2022-03-05 12:56

With food administration SerhiiP 2022-01-20 09:20
- With food administration dshah 2022-01-20 11:49

ODT in BE study Farmacevt 2022-01-18 16:01
- ODT in BE study dshah 2022-01-18 19:08

Biosimilars M.Vasu 2011-11-24 14:01
- Biosimilars Helmut 2011-11-24 14:44
  - Biosimilars M.Vasu 2011-11-28 12:33
    - Healthy subjects vs. patients Helmut 2011-11-28 12:56
    - Biosimilars drgunasakaran1 2012-02-06 13:57
  - Biosimilars Ben 2011-12-16 19:04
- Biosimilars Chiku 2012-02-03 06:43
  - Biosimilars drgunasakaran1 2012-02-10 11:33
    - Biosimilars Chiku 2012-02-10 12:03
      - Biosimilars Kumarnaidu2 2021-10-22 07:53

Admin contact
22,477 posts in 4,708 threads, 1,603 registered users;
17 visitors (0 registered, 17 guests [including 3 identified bots]).
Forum time: 22:12 CET (Europe/Vienna)

In these matters the only certainty is
that nothing is certain. Pliny the Elder

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz